Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Leukemia symbols : Abbv save search
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
| Email alert
Add to watchlist
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
research global leukemia therapeutics market
Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 3.59%
H: 0.0%
C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.28%
H: 0.66%
C: -0.14%
cell global leukemia market
AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
Published: 2023-06-09 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.06%
H: 1.18%
C: 0.45%
venclyxto leukemia show
Hairy Cell Leukemia Therapeutics Market Size to Grow by USD 177.85 million, Majority of Growth to Originate from North America - Technavio
Published: 2022-08-22 (Crawled : 07:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 2.39%
H: 1.09%
C: 1.09%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.66%
H: 0.1%
C: -1.43%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.08%
H: 0.49%
C: -1.15%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.49%
H: 1.11%
C: -0.39%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.35%
H: 0.5%
C: -1.23%
america leukemia therapeutics growth market
AbbVie Touts New Data for Rare Blood Cancer & Leukemia Treatments
Published: 2022-06-10 (Crawled : 16:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -3.55%
H: 0.0%
C: 0.0%
blood rare leukemia cancer treatment
New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
Published: 2022-06-10 (Crawled : 06:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -3.55%
H: 0.0%
C: 0.0%
venclyxto treatment leukemia
Acute Myeloid Leukemia (AML) Treatment Market size in APAC to grow by USD 277.03 Million | Driven by high incidence of acute myeloid leukemia | Technavio
Published: 2022-03-07 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 1.58%
H: 0.0%
C: -0.87%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
treatment myeloid leukemia leukemia acute myeloid leukemia aml
Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2021-2026: Ballooning Elderly Population - The Vital Growth Driver for AML Therapeutics
Published: 2021-12-06 (Crawled : 12:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
|
| O: -1.49%
H: 1.45%
C: 0.92%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 2.02%
H: 0.04%
C: -0.89%
IMNPQ | $0.001
|
Manufacturing
|
| O: 50.0%
H: 0.0%
C: -33.33%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -3.39%
H: 3.45%
C: 3.3%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
MEIP | $3.26 -2.17% -2.22% 7.4K
|
Health Technology
|
| O: -4.4%
H: 0.0%
C: 0.0%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -2.16%
H: 0.0%
C: 0.0%
CYCC | $2.3 28.49% 22.17% 430K
|
Health Technology
|
| O: -5.93%
H: 0.0%
C: 0.0%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 7.24%
H: 0.0%
C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
AGIO | $31.67 -0.44% -0.44% 540K
|
Health Technology
|
| O: -5.47%
H: 0.0%
C: 0.0%
myeloid leukemia leukemia therapeutics growth acute myeloid leukemia aml
Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $976.2 Billion by 2026
Published: 2021-08-11 (Crawled : 12:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.51%
H: 0.13%
C: -0.27%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.3%
H: 0.16%
C: -1.25%
MEIP | $3.26 -2.17% -2.22% 7.4K
|
Health Technology
|
| O: 0.37%
H: 0.36%
C: 0.0%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.09%
H: 1.32%
C: 0.35%
CYCC | $2.3 28.49% 22.17% 430K
|
Health Technology
|
| O: -0.19%
H: 0.19%
C: -0.76%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 1.73%
H: 0.34%
C: -7.14%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.52%
H: 0.38%
C: -0.44%
AGIO | $31.67 -0.44% -0.44% 540K
|
Health Technology
|
| O: 0.07%
H: 1.52%
C: -0.32%
myeloid leukemia leukemia acute myeloid leukemia aml
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
Published: 2021-06-12 (Crawled : 12:20) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
leukemia phase 3
FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Published: 2021-06-11 (Crawled : 14:04) - fda.gov
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.1%
C: -0.71%
fda granted approval leukemia myeloid leukemia grant acute myeloid leukemia
New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
Published: 2021-06-11 (Crawled : 06:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.1%
C: -0.71%
treatment leukemia
CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
Published: 2021-06-07 (Crawled : 16:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.31%
H: 1.24%
C: 0.27%
treatment potential therapy leukemia
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
leukemia
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Published: 2021-04-23 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.31%
H: 1.88%
C: 1.52%
myeloid leukemia positive therapy leukemia chmp acute myeloid leukemia
Global Leukemia Therapeutics Markets, 2016-2020 & 2021-2026 - Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, & Others
Published: 2021-04-21 (Crawled : 17:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.56%
H: 0.72%
C: 0.38%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.5%
H: 0.76%
C: -0.32%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.3%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.7%
H: 1.5%
C: 0.92%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.24%
H: 0.48%
C: 0.36%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.49%
H: 0.23%
C: -0.63%
immunotherapy stem cell therapy leukemia
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.